Newsroom

PARIS--(BUSINESS WIRE)--Waiv, anciennement Owkin Dx, une entreprise parisienne spécialisée dans les tests de précision de l'IA, a annoncé aujourd'hui avoir conclu une collaboration avec Daiichi Sankyo (TSE : 4568) pour diriger la découverte de biomarqueurs de pathologie numérique dans le cadre d'un programme de conjugués anticorps-médicament (ADC). Grâce à une expertise approfondie dans divers domaines de la pathologie et des données multimodales, et à un réseau mondial de données regroupant de...

PARIJS--(BUSINESS WIRE)--Waiv, voorheen Owkin Dx, een bedrijf gevestigd in Parijs dat AI-precisietesting katalyseert, maakte vandaag bekend dat het een samenwerkingsovereenkomst aangaat met Daiichi Sankyo (TSE: 4568) om digitale pathologiebiomarkerontdekking te leiden voor een ADC-programma (Antibody-Drug Conjugate = antilichaam-geneesmiddelconjugaat). Met grondige expertise in diverse pathologie- en multimodale data, en een wereldwijd datanetwerk dat academische instellingen, ziekenhuizen en l...

PARÍS--(BUSINESS WIRE)--Waiv, anteriormente Owkin Dx, empresa con sede en París especializada en impulsar pruebas de precisión basadas en inteligencia artificial, anunció hoy una colaboración con Daiichi Sankyo (TSE: 4568) para liderar el descubrimiento de biomarcadores mediante patología digital en el marco de un programa de conjugados anticuerpo-fármaco (ADC). Gracias a su amplia experiencia en datos patológicos y multimodales, así como a una red internacional de datos que integra institucion...

PARIGI--(BUSINESS WIRE)--Waiv, in precedenza Owkin Dx, un'azienda con sede a Parigi che promuove test di precisione basati sull'IA, ha annunciato di aver sottoscritto una collaborazione con Daiichi Sankyo (TSE: 4568) per guidare l'individuazione digitale di biomarcatori di patologie per un programma di coniugato anticorpo-farmaco (ADC). Grazie alle profonde competenze relative ai dati di patologie e multimodali eterogenei, e a una rete globale di dati che comprende istituti accademici, ospedali...

PARIS--(BUSINESS WIRE)--Waiv, ehemals Owkin Dx, ein in Paris ansässiges Unternehmen, das KI-gestützte Präzisionstests vorantreibt, gab heute bekannt, dass es eine Zusammenarbeit mit Daiichi Sankyo (TSE: 4568) eingegangen ist, um die Entdeckung digitaler pathologischer Biomarker für ein Antikörper-Wirkstoff-Konjugat-Programm (ADC) voranzutreiben. Mit fundiertem Fachwissen in den Bereichen Pathologie und multimodale Daten sowie einem globalen Datennetzwerk, das akademische Einrichtungen, Krankenh...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) to Angelini Pharma S.p.A. for $31.50 per share in cash.Halper Sadeh encourages Catalyst shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.The investigation concerns whether Catalyst and its board of dir...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: City of London Investment Management Company Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and...